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Abstract
Tumours are classified according to the most differentiated cells with the exception of carcinomas
where a few tumour cells show neuroendocrine differentiation. In this case these cells are regarded
as redifferentiated tumour cells, and the tumour is not classified as neuroendocrine. However, it is
now clear that normal neuroendocrine cells can divide, and that continuous stimulation of such
cells results in tumour formation, which during time becomes increasingly malignant. To
understand tumourigenesis, it is of utmost importance to recognize the cell of origin of the tumour
since knowledge of the growth regulation of that cell may give information about development and
thus possible prevention and prophylaxis of the tumour. It may also have implications for the
treatment. The successful treatment of gastrointestinal stromal tumours by a tyrosine kinase
inhibitor is an example of the importance of a correct cellular classification of a tumour. In the
future tumours should not just be classified as for instance adenocarcinomas of an organ, but more
precisely as a carcinoma originating from a certain cell type of that organ.
During tumourigenesis cellular phenotype changes as
mutations occur and accumulate. Most mutations result
in functional loss. However, when mutations affect an
inhibitory mechanism, the net result may be a gain of
function. Typically in malignant cells such a loss results in
increased proliferation and/or gain in the ability to invade
surrounding structures or to spread from the tissue of ori-
gin (metastasize). In order to grow beyond a critical cell
mass new blood vessels have to develop in the tumour
(angiogenesis). Morphologically, tumour cells change
their appearance at the cytological level (cellular atypia)
and their growth pattern (dysplasia). Such gradual
changes are typically seen in tumours of the colon where
adenomas with different degrees of dysplasia or overt car-
cinomas are seen [1], occasionally in the same patient.
Similarly, a gradual transition from normal to dysplastic
to malignant growth can be seen in the enterochromaffin
like (ECL) cells in the oxyntic mucosa [2] particularly after
long-term hypergastrinemia in man [3] as well as animals
[4]. It is well-known that the cells of highly malignant
tumours may have changed so much that the cell of origin
may be difficult to recognize in so-called dedifferentiated
or anaplastic tumours. Often, however, parts of the
tumour are more differentiated, and it is generally
accepted that a tumour is classified according to its most
differentiated part. There is, however, one exception to
this classification, namely when a few neuroendocrine
tumour cells are found among dedifferentiated and ana-
plastic tumour cells [5]. In such cases the tumours are clas-
sified according to the presumed origin of the majority of
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the cells, and the neuroendocrine differentiated tumour
cells are neglected. These neuroendocrine tumour cells are
considered to be the result of a neuroendocrine redifferen-
tiation of an exocrine derived tumour cell [6,7].
Neuroendocrine tumours
Neuroendocrine tumours are generally difficult to classify
into benign or malignant tumours [8]. Tumours with a
highly differentiated and almost normal phenotype may
prove to be malignant based upon the detection of local
invasion or metastasis, which may be found years after
removal of the initial tumour [9]. Thus, neuroendocrine
tumours may morphologically look rather benign and
grow slowly, but nevertheless they have the ability to
metastasize. This property may be explained by an effect
of their normal mediators on the surrounding tissues.
Thus, these mediators like for instance histamine from the
ECL cell, may dilate the vascular bed and at the same time
increase the permeability of the capillaries making it eas-
ier for the tumour cells to gain access to the blood [10].
Moreover, histamine and other substances from neuroen-
docrine cells have a stimulatory effect on angiogenesis
[11]. In other words, many of these neuroendocrine cells
normally produce substances making it easier for these
cells to grow and disseminate. This may also explain why
such tumours may not need so many mutations and
accordingly not be so changed phenotypically as other
tumours, while still having the ability to metastasize.
In many tumours classified as adenocarcinomas based
upon a glandular growth pattern and/or tumour cells pos-
itive for PAS or Alcian blue and thus believed to contain
mucin, there are tumour cells with neuroendocrine prop-
erties [12]. These neuroendocrine cells are believed to be
redifferentiated exocrine derived tumour cells [6,7]. Con-
sequently, these cells do not have any implication for the
classification of the tumour. However, when increasing
the sensitivity of immunohistochemistry by tyramide sig-
nal amplification (TSA) [13], the number of chrom-
ogranin A (CgA) positive tumour cells are greatly
increased [14]. CgA occurs exclusively in the neuroendo-
crine granules and such immunoreactivity is thus specific
for neuroendocrine derived cells [15]. Thus, neuroendo-
crine tumour cells in anaplastic tumours may represent
the most differentiated tumour cells in the dedifferenti-
ated neuroendocrine tumour. If so, these tumours must
have their origin in neuroendocrine cells, which have
gradually become more malignant. In the oxyntic mucosa
of the stomach the ECL cell has a key position in the reg-
ulation of acid secretion [16], and this cell is regulated
both functionally as well as trophically by gastrin [16,17].
Tumours developing from the ECL cell are classified into
three types according to presumed aetiology: groups I and
II being related to hypergastrinemia whereas group III
tumours apparently occur in normogastrinemic individu-
als [18]. Although group I ECLomas also obviously may
become highly malignant [3], it is clear that the type III
ECLomas generally are more malignant than those occur-
ring in hypergastrinemic individuals [18]. This indicates
that the ECL cells of the type III ECLomas must have
become less gastrin dependent than normal ECL cells
[19]. Nevertheless, ECL cell derived tumours induced by
chronic hypergastrinemia [20] may also become increas-
ingly malignant [3], and the gastric adenocarcinomas in
patients with hypergastrinemia secondary to severe
chronic atrophic gastritis may have been derived from the
ECL cell and thus be misclassified neuroendocrine carci-
nomas [21]. The gastric carcinomas in patients with perni-
cious anaemia could be classified as neuroendocrine
tumours after immunohistochemistry for CgA with the
help of TSA technique [21]. The TSA technique improves
the sensitivity without reducing the specificity since this
depends on the specificity of the primary antibody only.
Moreover, the signet ring tumour cells in gastric carcino-
mas, believed to be mucin producing, are positive for neu-
roendocrine markers [22]. It is worth recalling that PAS
staining is not specific for mucin, since glycoproteins in
general are stained by PAS [23]. Furthermore, many neu-
roendocrine cells normally, or in pathological conditions
[24], produce glycohormones which may be classified as
glycoproteins or glycopeptides. Finally, the secre-
togranins, being exclusively expressed in neuroendocrine
cells, are also glycoproteins [25]. Accordingly, there is a
misunderstanding that PAS positivity is specific for exo-
crine cells. Reclassification of malignant gastric tumours
from adenocarcinomas of presumptive of exocrine origin
into malignant neuroendocrine carcionomas has previ-
ously been done in the tumours occurring spontaneously
in mastomys [26], in rodents after life-long hypergastrine-
mia due to loxtidine dosing [27,28] and in man [29].
Many do not realize that neuroendocrine cells are
multipotent [30]. Transformation of neuroendocrine cells
in the bronchi into a squamous epithelium has been
described in Syrian golden hamsters [31]. Moreover the
squamous epithelial cancer cells in the bronchi may show
neuroendocrine differentiation [32], suggesting that the
two types of bronchial carcinomas most closely related to
tobacco smoking, small cell and squamous cell carcino-
mas [33], both may originate from neuroendocrine cells.
Thus, the tumourigenic substance(s) in tobacco smoke,
which is neither nicotine [34] nor CO [35], may have its
main effect on the bronchial neuroendocrine cells. Hith-
erto, the prevailing theory has been that neuroendocrine
cells and tumours from neuroendocrine cells are derived
from stem cells that differentiate into neuroendocrine cell
type. However, it is well known that rodent neuroendo-
crine cells do proliferate [36] and also in man it is obvi-
ously difficult to explain how clusters of neuroendocrine
cells (micro-carcinoids) far from the proliferation zone ofJournal of Experimental & Clinical Cancer Research 2008, 27:70 http://www.jeccr.com/content/27/1/70
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exocrine cells, can occur without self-replication. Moreo-
ver, we have been able to describe self-replication of neu-
roendocrine cells in cancer cells both in the prostate [37]
and gastric carcinomas [14]. Very recently, indeed adult
beta-cells of the islets of Langerhans were described to be
formed by self-duplication rather than differentiation
from stem-cell [38].
Classification of the cell of origin in cancers
To make a correct classification of cellular origin of
tumours it is necessary to use immunohistochemistry
with antibodies directed against antigens with high specif-
icity, and apply the methods with the highest sensitivity.
Is it of importance to make a correct cellular classification
of tumours? If the correct cellular classification of
tumours does not give any indication of prognosis or
treatment, it may be argued that the effort is pointless.
This is, however, not true, since a correct cellular classifi-
cation indicates the pathogenesis of the tumour and thus
may be important for the prevention of the tumour based
upon knowledge of the growth regulation of the cell of
origin. Since the more differentiated type I gastric carci-
noids are the most common type and gastrin plays such a
dominant role in the trophic regulation of the ECL cell,
hypergastrinemia will be expected to increase most
tumours of ECL cell origin. Only ECL cell tumours with
very early and activating mutations in the gastrin receptor
can be assumed to be completely gastrin independent.
What the case is in the so-called ECL cell tumours of type
III [18] remains to be shown. On the other hand, somato-
statin acting via the somatostatin subtype 2 receptor has a
negative trophic effect on the ECL cell, which may be used
to treat ECL cell derived carcinoids at an early stage [39].
Furthermore, gastrointestinal stromal tumours (GIST)
derived from cells of Cajal, possibly being of neural crest
origin, may now be treated rather successfully with an
inhibitor of a kinase [40], which regulates the prolifera-
tion of the Cajal cells. After such treatment became avail-
able, these types of tumours have been diagnosed more
often. This is an example of a change in classification after
an effective treatment of a sub-group of tumours has been
recognized. Vice versa, a correct cellular classification of
tumours in the future, including knowledge about genetic
and cellular mechanisms regulating the growth of the
cells, may be expected to tailor drug development and
thus give rise to new treatment modalities.
In conclusion, a correct classification of the cell of origin
of carcinomas will greatly increase our biological under-
standing of carcinogenesis, give rise to new possibilities
for prevention and early treatment, and possibly to tailor
new drugs for the treatment of the tumours.
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